Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?

ABSTRACT: Glioblastoma remains the most malignant and intrinsically resistant brain tumour in adults. Despite intensive research over the past few decades, through which numerous potentially druggable targets have been identified, virtually all clinical trials of the past 20 years have failed to improve the outcome for the vast majority of GBM patients. The observation that small subgroups of patients displayed a therapeutic response across several unsuccessful clinical trials suggests that the GBM patient population probably consists of multiple subgroups that probably all require a distinct therapeutic approach. Due to extensive inter- and intratumoral heterogeneity, assigning the right therapy to each patient remains a major challenge. Classically, bulk genetic profiling would be used to identify

SUBMITTER: Panovska D 

PROVIDER: S-EPMC9369403 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature